This article in the Cleveland Plain Dealer puts the departure of Dr Rezai for OSU in needed context. That it wasn't hard for USU to lure a clinician/researcher of this stature says a lot about the Cleveland Clinic!
This bit, near the bottom of the article, deserves to be highlighted:
Medtronic, the Minneapolis-based device manufacturer known for its heart pacemakers, noted in its May earnings report that annual revenue on devices for neuromodulation increased 9 percent to $1.43 billion last year. A spokeswoman said the company expects that trajectory to continue to climb.
That's serious money. No wonder St. Jude wants in!
